Search This Blog

Wednesday, May 4, 2016

FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma (NYSE:LLY)

Olaratumab Previously Received Breakthrough Therapy Designation



FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.